Search

Displaying results 2531 - 2540 of 5895 in total
  1. Drug

    Cerulenin

    go.drugbank.com/drugs/DB01034
    Experimental

    In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. … Cerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of fatty acids and sterols.

  2. Drug

    Eptifibatide

    go.drugbank.com/drugs/DB00063
    ApprovedInvestigational

    Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. … Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics.

  3. Drug

    Ty800

    go.drugbank.com/drugs/DB04989
    Investigational

    The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of <i>S. typhi</i>. It is being developed by AVANT Immunotherapeutics, Inc. … Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against <i>Salmonella typhi</i>, the cause of typhoid fever.

  4. Drug

    Chenopodium album pollen

    go.drugbank.com/drugs/DB10368
    Approved

    Chenopodium album pollen is the pollen of the Chenopodium album plant. Chenopodium album pollen is mainly used in allergenic testing.

    Mixtures: Number Two Weed Mixture
  5. Drug

    Salmon calcitonin

    go.drugbank.com/drugs/DB00017
    ApprovedInvestigational

    Synthetic peptide, 32 residues long formulated as a nasal spray.

  6. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier.

  7. Drug

    Lesinurad

    go.drugbank.com/drugs/DB11560
    ApprovedWithdrawn

    Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target

  8. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

  9. Drug

    Scopolamine

    go.drugbank.com/drugs/DB00747
    ApprovedInvestigational

    [A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981. … [A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants.

  10. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. … Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo